Olesoxime

Olesoxime

Olesoxime (TRO19622) is the lead compound of Trophos' proprietary cholesterol-oxime compound family of mitochondrial pore modulators. [1]

It is a molecule that has a cholesterol-like structure and displays strong neuroprotective properties. TRO19622 is as effective as a cocktail of three neurotrophic factors in keeping motor neurons alive in culture.[citation needed]

Preclinical studies have demonstrated that the compound promotes the function and survival of neurons and other cell types under disease-relevant stress conditions through interactions with the mitochondrial permeability transition pore (mPTP).[2]

Olesoxime has successfully completed phase I studies in healthy volunteers and phase Ib studies in Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy patients. These clinical trials showed that the product is well tolerated and has an excellent safety profile. They also showed that once-a-day oral dosing achieves the predicted exposure levels, required for efficacy, based on preclinical models.[3] [4]

Drug interaction studies with riluzole, the only registered treatment for ALS, showed no interaction of TRO19622 on riluzole pharmacokinetics.

Olesoxime (TRO19622) is currently being developed for the treatment of two motor neuron diseases: Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA).

References

  1. ^ http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5002
  2. ^ Bordet, Thierry; Buisson, Bruno; Michaud, Magali; Drouot, Cyrille; Galéa, Pascale; Delaage, Pierre; Akentieva, Natalia P.; Evers, Alex S. et al. (2007). "Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis". The Journal of pharmacology and experimental therapeutics 322 (2): 709–20. doi:10.1124/jpet.107.123000. PMID 17496168. 
  3. ^ "Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy". ClinicalTrialsFeeds.org. 05 February 2010. http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00876538. Retrieved 3 October 2010. 
  4. ^ "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". ClinicalTrialsFeeds.org. May 2010. http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00868166. Retrieved 3 October 2010. 

Further reading


Wikimedia Foundation. 2010.

Игры ⚽ Нужна курсовая?

Look at other dictionaries:

  • Amyotrophic lateral sclerosis — This article is about progressive Motor Neuron Disease (MND) affecting both the upper motor neurons and lower motor neurons. For MND affecting either but not necessarily both, see Motor neurone disease. ALS redirects here. For other uses, see ALS …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”